- Companies
- BostonGene
BostonGene Funding, Investors & Competitors
BostonGene has raised $200M across 2 funding rounds, most recently a $150M Series B in April 2022.
Last BostonGene funding round
$150M
Series B · Apr 2022
Cumulative funding BostonGene raised
$200M
across 2 funding rounds
Key investors in BostonGene
NEC
Japan Industrial Partners
Impact Investment Capital
About BostonGene
BostonGene is a Waltham-based precision oncology company applying genomic profiling and AI analytics to match cancer patients with therapies. Launched in 2016, its TumorGMO assay sequences DNA, RNA, and proteomics from biopsies, analyzing over 50,000 tumor samples annually. BostonGene partners with hospitals like City of Hope and Dana-Farber Cancer Institute to guide treatments using FDA-approved drugs and clinical trials.
Founded
2015
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Services, Subscription
BostonGene Funding History
BostonGene has raised a total of $200M across 2 funding rounds.
BostonGene's first fundraising round was a $50M Series A in April 2019. The most recent completed round was a $150M Series B in April 2022.
BostonGene funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Apr 2022 | Series B | NEC (lead); Japan Industrial Partners; Impact Investment Capital | $150M | BostonGene is a precision oncology company headquartered in Waltham, Massachusetts, founded in 2015, that develops an AI-powered platform for molecular and immune profiling of tumors. Its core product, the Tumor Portrait test (also called Molecular Portrait Test), integrates genomic data, analytics, and machine learning to analyze tumor biology, microenvironment, and host immunity, helping oncologists identify personalized cancer therapies, predict treatment responses, and improve patient outcomes. On April 6, 2022, BostonGene closed a $150 million Series B funding round led by NEC Corporation, with participation from Impact Investment Capital and Japan Industrial Partners. The round propelled the company to unicorn status at a multi-billion dollar valuation, bringing total funding to around $200 million at that point. Proceeds are earmarked for accelerating R&D, expanding clinical and research partnerships, scaling operations, and enabling international growth, particularly in Japan and Asia via a planned joint venture with NEC leveraging its AI and infrastructure capabilities. The financing builds on prior rounds, including a Series A, and supports adoption of BostonGene's tests by U.S. academic and community oncologists. NEC's involvement aligns with its healthcare and life sciences unit under its 2025 Mid-term Management Plan, aiming to advance global clinical outcomes through AI-driven precision medicine. |
| Apr 2019 | Series A | NEC (lead) | $50M | BostonGene Corporation, founded in 2015, is a Boston-based biomedical software company developing a precision medicine computing platform for cancer treatment, utilizing genome and transcriptome sequencing to create molecular portraits of tumors. The platform supports personalized cancer therapy by analyzing tumor profiles, microenvironment, and host immunity, with early adoption by leading U.S. cancer centers and a robust intellectual property portfolio. On April 25, 2019 (announced Tokyo) and April 24, 2019 (Boston), NEC Corporation made a US$50M Series A strategic investment in BostonGene. The proceeds supported scaling the platform, expanding development efforts, advancing collaborations, growing the team, and forming synergies with NEC's Health Tech business to enhance AI-driven cancer immunotherapy and improve patient survival and quality of life. BostonGene's leadership, including President and CEO Andrew Feinberg, highlighted the platform's transformative potential validated by early successes and market need. NEC's Osamu Fujikawa emphasized BostonGene's leadership in precision medicine innovation. This round preceded a 2022 Series B. Aggregated funding data across sources confirms $50M Series A in 2019 from NEC, with total raised reaching $200M by 2022 Series B ($150M led by NEC with Impact Investment Capital and Japan Industrial Partners). |
Who has invested in BostonGene?
3 investors have backed BostonGene across its funding rounds, including NEC, Japan Industrial Partners and Impact Investment Capital.
Lead investors include NEC.
BostonGene Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Apr 2019 | ||
This data is available for Pro users. Sign up to see all 3 BostonGene investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialBostonGene Competitors
BostonGene competitors include listed companies like IQVIA, ICON plc and Privia Health, and private ones like Hippocratic AI, Innovaccer and NantHealth.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Private | - | - | $3.5B | - | ||
| Private | $250M | - | $3.5B | 13.8x | ||
| Publicly listed | $2.1B | $44M | $2.6B | 0.9x | ||
| Private | $58M | - | $2B | - |
BostonGene Public Comps
BostonGene is still privately-owned, but its public comps include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Revvity, Solventum, Tempus AI, ICON plc and Pro Medicus.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $16B | $3.4B | 3.6x | 3.4x | 17.2x | 14.8x | |||
| $3.2B | $965M | 11.1x | 10.2x | 36.9x | 22.4x | |||
| $4.3B | $1.5B | 9.5x | 8.9x | 27.1x | 24.9x | |||
| $7.9B | $3.2B | 6.1x | 5.7x | 15.2x | 14.6x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
| $2.9B | $735M | 6.5x | 6.6x | 25.4x | 21.0x | |||
| $8.3B | $2.5B | 2.4x | 2.4x | 7.8x | 8.9x | |||
| $1.3B | ($131M) | 12.0x | 10.1x | (116.0x) | 346.0x | |||
This data is available for Pro users. Sign up to see all BostonGene competitors and their valuation data. Start Free Trial | ||||||||
Common questions about BostonGene
| When was BostonGene founded? | BostonGene was founded in 2015. |
| Where is BostonGene headquartered? | BostonGene is headquartered in Boston, MA, United States. |
| Is BostonGene publicly listed? | No, BostonGene is a private, VC-backed company. |
| How much funding has BostonGene raised? | BostonGene has raised $200M across 2 funding rounds. |
| What was BostonGene's last funding round? | BostonGene's last funding round was a $150M Series B in April 2022, led by NEC. |
| Who are BostonGene's investors? | BostonGene's investors include NEC, Japan Industrial Partners and Impact Investment Capital. |
| Which companies are comparable to BostonGene? | Companies comparable to BostonGene include IQVIA, ICON plc, Hippocratic AI, Innovaccer, Privia Health and NantHealth. |
See companies similar to BostonGene
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




